Webinar Abstract:

Targeted protein degradation is redefining what’s possible in modern drug discovery. By harnessing the cell’s own machinery to eliminate disease-causing proteins, degraders and molecular glues are moving science beyond traditional inhibition—and into a new era of precision and control.

This webinar brings together experts from two leading research centers—one pioneering next-generation molecular glue discovery, and the other advancing VHL-based degrader platforms for oncology. Together, they’ll explore the science, strategy, and design principles that are breaking the old rules of drug development and opening up vast new therapeutic space.

revvity-breaking-boundaries-in-targeted-protein-degradation-on-demand-webinar-thumbnail-img

Who Should Attend:

Scientists and leaders in medicinal chemistry, chemical biology, and drug discovery.
Researchers exploring emerging therapeutic modalities and the future of small molecules.
Drug Discovery professionals who are interested in knowing how degraders and molecular glues are reshaping traditional drug development workflows.

Why You Should Join:

Hear from top-tier research institutions at the forefront of protein degradation science.
Gain practical insights into how molecular glues and PROTACs are expanding druggable targets.
Understand how evolving assay cascades and screening methods are helping advance compounds beyond the traditional Rule of 5 (Ro5) limitations.

What You’ll Learn:

The key mechanistic and design differences between degraders and molecular glues.
How leading teams are engineering selectivity and efficacy across complex protein systems.
The changing landscape of assay cascades and experimental strategies needed to progress non-traditional, beyond Ro5 compounds.
Where the field is headed next—and how to position your organization at the cutting edge.

Speakers:

Zev Wisotsky
PhD, Senior Principal Marketing Manager, Biologics Solutions, Revvity Signals

Zev Wisotsky is a Senior Principal Marketing Manager for Biologics Solutions at Revvity Signals. His scientific training and research background include neuroscience, biochemistry, molecular biology and drug discovery. He has spent almost 10 years in software in go-to-market teams across industries with a heavy focus on biopharma/biotech R&D.

Dr Nicholas Cundy
Senior Scientific Officer – Medicinal Chemistry, Centre for Cancer Drug Discovery, The Institute of Cancer Research (London, UK)

Nick obtained his PhD in Organic Chemistry from the University of Birmingham (UK) and undertook a postdoctoral Fellowship at the University of Ottawa (Canada) before moving to the Institute of Cancer Research as a medicinal chemist. Since joining the ICR, Nick has worked on inhibitor and degrader drug discovery projects.

Dr. Gisele Nishiguchi,
Targeted Protein Degradation Center Leader, Chemical Biology and Therapeutics Department at St. Jude Children’s Research Hospital

Gisele obtained her PhD in organic chemistry from the University of California, Santa Barbara. She then joined Novartis as a medicinal chemist and worked on several hit-to-lead and lead optimization projects, resulting in two oncology clinical candidates. In 2018, she moved to St. Jude Children’s Research Hospital, where she currently leads the Targeted Protein Degradation Center.

* By submitting my personal data, I acknowledge that Revvity, Inc. and its affiliates ("Company") will process my personal data provided above consistent with the Privacy Policy . I also agree to receive communications from Revvity Signals and understand that I can unsubscribe at any time.